KDM1A, PHF13 and miR6859 epigenetic regulators were selected from those 200 genes that showed the greatest difference in expression levels in the case of comparing ruxolitinib-treated and untreated CLL cells. The gene discussed is KDM1A; the disease is B-cell chronic lymphocytic leukemia.